In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.
The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.
